Market closed

HCW Biologics/$HCWB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Ticker

$HCWB
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Miramar, United States

Employees

45
Website
www.hcwbiologics.com

HCW Biologics Metrics

BasicAdvanced
$16M
-
-$1.00
0.84
-

$16M

0.84

$1.93

$0.28

389K

0.088

0.069

-64.825

-129.687

-93.78%

-71.95%

-537.24%

3.875

-1.38

-1.38

-0.707

22.27%

80.90%

-5.17%

11.13%

What the Analysts think about HCW Biologics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for HCW Biologics stock.

HCW Biologics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HCW Biologics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

HCW Biologics News

AllArticlesVideos
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

GlobeNewsWire·2 hours ago
HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

GlobeNewsWire·3 weeks ago
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HCWB

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for HCW Biologics stock?

HCW Biologics (HCWB) has a market cap of $16M as of January 15, 2025.

What is the P/E ratio for HCW Biologics stock?

The price to earnings (P/E) ratio for HCW Biologics (HCWB) stock is 0 as of January 15, 2025.

Does HCW Biologics stock pay dividends?

No, HCW Biologics (HCWB) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next HCW Biologics dividend payment date?

HCW Biologics (HCWB) stock does not pay dividends to its shareholders.

What is the beta indicator for HCW Biologics?

HCW Biologics (HCWB) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.